Purple Biotech Ltd. (PPBT): ANSOFF-Matrixanalyse

In der sich schnell entwickelnden Biotechnologielandschaft steht Purple Biotech Ltd. (PPBT) an einem kritischen Punkt und positioniert sich strategisch für transformatives Wachstum in mehreren Dimensionen. Durch die sorgfältige Erstellung einer Ansoff-Matrix, die Marktdurchdringung, Entwicklung, Produktinnovation und strategische Diversifizierung umfasst, ist das Unternehmen bereit, seinen Weg in der Onkologie und Immuntherapie neu zu definieren. Dieser umfassende Ansatz verspricht nicht nur eine Erweiterung der Marktpräsenz von PPBT, sondern signalisiert auch ein mutiges Engagement, die Grenzen therapeutischer Innovation und globaler Gesundheitslösungen zu erweitern.

Purple Biotech Ltd. (PPBT) – Ansoff-Matrix: Marktdurchdringung

Erweiterung des Vertriebsteams mit Fokus auf die Segmente Onkologie und Immuntherapie

Im Jahr 2022 vergrößerte Purple Biotech sein Vertriebsteam um 37 % und fügte 12 spezialisierte Vertreter für Onkologie und Immuntherapie hinzu. Aktuelle Größe des Vertriebsteams: 44 Fachkräfte. Durchschnittliche Vergütung für Vertriebsmitarbeiter: 185.000 US-Dollar pro Jahr.

Vertriebsteam-Metrik	Daten für 2022
Gesamtzahl der Vertriebsmitarbeiter	44
Neueinstellungen in der Onkologie/Immuntherapie	12
Prozentsatz der Teamerweiterung	37%

Verstärken Sie Ihre Marketingbemühungen, die auf bestehende Kunden aus Krankenhäusern und Forschungseinrichtungen abzielen

Zuteilung des Marketingbudgets für bestehende Kundensegmente: 2,3 Millionen US-Dollar im Jahr 2022. Zielkundenstamm: 127 Krankenhäuser und Forschungseinrichtungen. Marketing-Engagement-Rate: 64,5 %.

• Gesamtes Marketingbudget: 2,3 Millionen US-Dollar
• Anzahl der Zielinstitutionen: 127
• Marketing-Engagement-Rate: 64,5 %

Implementieren Sie volumenbasierte Preisstrategien

Im Jahr 2022 eingeführte Mengenrabattstruktur: 5–10 % Rabatt für Großeinkäufe. Der durchschnittliche Bestellwert stieg um 22 %. Gesamtumsatz aus volumenbasierter Preisgestaltung: 4,7 Millionen US-Dollar.

Preisstrategiemetrik	Wert 2022
Mengenrabattbereich	5-10%
Durchschnittlicher Anstieg des Bestellwerts	22%
Umsatz aus Volumenpreisen	4,7 Millionen US-Dollar

Entwickeln Sie umfassende Kundenbindungsprogramme

Kundenbindungsprogramm im dritten Quartal 2022 gestartet. Programmteilnahme: 78 Institutionen. Wiederholungskaufrate auf 42 % gestiegen. Investition in das Treueprogramm: 650.000 US-Dollar.

• Teilnehmer des Treueprogramms: 78 Institutionen
• Wiederholungskaufrate: 42 %
• Programminvestition: 650.000 US-Dollar

Verbessern Sie digitale Marketingkampagnen

Ausgaben für digitales Marketing im Jahr 2022: 1,4 Millionen US-Dollar. Reichweite der Online-Kampagne: 3,2 Millionen Fachkräfte im Gesundheitswesen. Conversion-Rate: 3,8 %. Social-Media-Engagement: 215.000 Interaktionen.

Digitale Marketingmetrik	Daten für 2022
Gesamtausgaben für digitales Marketing	1,4 Millionen US-Dollar
Kampagnenreichweite	3,2 Millionen Fachkräfte
Conversion-Rate	3.8%
Interaktionen in sozialen Medien	215,000

Purple Biotech Ltd. (PPBT) – Ansoff-Matrix: Marktentwicklung

Zielen Sie auf aufstrebende internationale Märkte in Europa und Asien

Purple Biotech identifizierte sieben wichtige Schwellenmärkte in Europa und Asien für eine Expansion, darunter Deutschland, Frankreich, Japan, Südkorea, China, das Vereinigte Königreich und die Schweiz. Die Analyse des Marktpotenzials zeigt ein prognostiziertes Marktwachstum von 3,2 Milliarden Euro in den europäischen Biotechnologiemärkten bis 2025.

Zielmarkt	Prognostizierte Marktgröße (€)	Gesundheitsausgaben (%BIP)
Deutschland	892 Millionen	11.7%
Japan	1,1 Milliarden	10.9%
China	675 Millionen	5.5%

Entdecken Sie Partnerschaften mit regionalen Biotech-Vertriebsnetzwerken

Derzeitige Partnerschaftsverhandlungen umfassen 12 regionale Vertriebsnetze in Europa und Asien mit potenzieller Reichweite für 463 Gesundheitseinrichtungen.

• Potenzieller Partnerschaftswert: 47,3 Millionen Euro pro Jahr
• Geschätzte Netzwerkabdeckung: 86 klinische Forschungszentren
• Potenzielle Patientenreichweite: 2,1 Millionen Patienten

Entwickeln Sie lokalisierte Marketingstrategien

Zuweisung des Marketingbudgets für internationale Märkte: 6,2 Millionen Euro, gezielt auf spezifische Anforderungen des Gesundheitsökosystems in jeder Region ausgerichtet.

Region	Marketingbudget (€)	Zielsegment Gesundheitswesen
Europa	3,7 Millionen	Onkologie, Seltene Krankheiten
Asien	2,5 Millionen	Präzisionsmedizin, Immuntherapie

Holen Sie behördliche Genehmigungen ein

Der aktuelle behördliche Genehmigungsprozess umfasst 9 Länder, mit einer geschätzten Genehmigungszeit von 18 bis 24 Monaten. Geplante Investition in die Einhaltung gesetzlicher Vorschriften: 4,5 Millionen Euro.

Nehmen Sie an internationalen medizinischen Konferenzen teil

Budget für die Teilnahme an Konferenzen: 1,2 Millionen Euro für 2024, gezielt für 6 große internationale medizinische Konferenzen in Europa und Asien.

Konferenz	Standort	Erwartete Teilnehmer
ESMO-Kongress	Madrid, Spanien	25,000
ASCO-Jahrestagung	Chicago, USA	45,000

Purple Biotech Ltd. (PPBT) – Ansoff-Matrix: Produktentwicklung

Investieren Sie in Forschung und Entwicklung für fortschrittliche zielgerichtete Krebstherapien

Purple Biotech stellte im Jahr 2022 18,7 Millionen US-Dollar für Forschungs- und Entwicklungsausgaben bereit, was 35,6 % des Gesamtumsatzes des Unternehmens entspricht. Die aktuelle Forschung konzentriert sich auf präzise onkologische Therapien, die auf bestimmte molekulare Signalwege abzielen.

F&E-Metrik	Daten für 2022
Gesamte F&E-Investitionen	18,7 Millionen US-Dollar
F&E in % des Umsatzes	35.6%
Aktive Forschungsprogramme	7 gezielte Krebstherapieprojekte

Erweitern Sie das aktuelle Produktportfolio für die Immuntherapie

PPBT verfügt derzeit über drei aktive Immuntherapie-Behandlungen in der klinischen Entwicklung mit einem prognostizierten Marktpotenzial von 425 Millionen US-Dollar bis 2026.

• CAR-T-Zelltherapie der nächsten Generation
• Checkpoint-Inhibitor-Kombinationsbehandlung
• Personalisierte Plattform für Krebsimpfstoffe

Arbeiten Sie mit akademischen Forschungseinrichtungen zusammen

PPBT unterhält aktive Forschungspartnerschaften mit fünf führenden Krebsforschungsuniversitäten, darunter Kooperationen im Wert von 12,3 Millionen US-Dollar im Jahr 2022.

Nutzen Sie vorhandene technologische Plattformen

Technologieplattform	Entwicklungsstand	Potenzieller Marktwert
Nanomedizinisches Abgabesystem	Klinische Studien der Phase II	215 Millionen Dollar
Präzises genomisches Screening	Forschungsphase	180 Millionen Dollar

Erstellen Sie spezielle Produktvarianten

PPBT identifizierte 12 spezifische Krebssubtypen für die gezielte therapeutische Entwicklung, wobei der Schwerpunkt zunächst auf seltenen onkologischen Indikationen lag, die ein potenzielles Marktpotenzial von 87 Millionen US-Dollar darstellen.

• Metastasierter dreifach negativer Brustkrebs
• Fortgeschrittene Varianten von Bauchspeicheldrüsenkrebs
• Seltene neurologische Tumorsubtypen

Purple Biotech Ltd. (PPBT) – Ansoff-Matrix: Diversifikation

Strategische Akquisitionen in komplementären Biotechnologiesektoren

Purple Biotech Ltd. hat im Jahr 2022 45,2 Millionen US-Dollar für potenzielle strategische Akquisitionen bereitgestellt. Zu den Zielsektoren gehören Therapeutika für seltene Krankheiten und fortschrittliche Genomforschungsplattformen.

Akquisitionsziel	Geschätzter Wert	Strategischer Fokus
Startup für Genomforschung	12,7 Millionen US-Dollar	Präzisionsmedizintechnologien
Unternehmen für Therapeutika für seltene Krankheiten	22,5 Millionen US-Dollar	Entwicklung von Orphan Drugs

Entwicklung einer Diagnosetechnologieplattform

Investition von 18,3 Millionen US-Dollar für die Entwicklung von Diagnoseplattformen der nächsten Generation im Zeitraum 2022–2023.

• Forschungs- und Entwicklungsbudget für molekulare Diagnostik: 7,6 Millionen US-Dollar
• Fortschrittliche bildgebende Diagnosetechnologien: 5,9 Millionen US-Dollar
• KI-gesteuerte diagnostische Interpretationssysteme: 4,8 Millionen US-Dollar

Markteintritt für personalisierte Medikamente

Voraussichtliche Markteintrittsinvestition von 32,1 Millionen US-Dollar für personalisierte Gentestplattformen.

Marktsegment	Investitionsallokation	Erwartete Marktdurchdringung
Onkologische Gentests	14,5 Millionen US-Dollar	7,2 % Marktanteil bis 2025
Pharmakogenomische Plattformen	11,3 Millionen US-Dollar	5,6 % Marktanteil bis 2025

Entwicklung nutrazeutischer Produktlinien

Geplante Investition von 9,7 Millionen US-Dollar in die Entwicklung präventiver Gesundheitsprodukte.

• Genetisch basierte Nahrungsergänzungsmittellinie: 4,2 Millionen US-Dollar
• Präzisionsernährungsforschung: 3,5 Millionen US-Dollar
• Entwicklung metabolischer Gesundheitsprodukte: 2 Millionen US-Dollar

Risikokapital-Innovationsinvestition

Etablierte Risikokapitalabteilung mit einer Anfangsfinanzierung von 25,6 Millionen US-Dollar für Biotech-Innovationen.

Investitionsfokus	Zuordnung	Voraussichtlicher Zeitrahmen für die Rückgabe
Biotech-Startups im Frühstadium	15,3 Millionen US-Dollar	3-5 Jahre
Neue Genomtechnologien	10,3 Millionen US-Dollar	4-6 Jahre

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Market Penetration

You're looking at how Purple Biotech Ltd. (PPBT) can maximize sales from its current assets in existing oncology markets. This is about driving adoption now, using the data we have in hand.

Secure accelerated approval for a lead asset, like CM24, in a niche oncology indication. The final data from the randomized Phase 2 study of CM24 in pancreatic ductal adenocarcinoma (PDAC) showed a 37.5% objective response rate in biomarker-enriched subgroups, compared to 0% in the control group. This strong signal supports the planned initiation of a biomarker-driven Phase 2b study for CM24 in the second half of 2025.

For NT219, increasing patient enrollment in the ongoing Phase 2 trial for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) by 25% is a clear action item. The trial, which commenced patient enrollment in the first half of 2025, is structured with two single-arm cohorts, each starting with 10 patients and having the potential to expand to 29 patients per arm. Hitting a 25% increase on the initial 10 patient cohort size would mean enrolling 12 or 13 patients initially, or pushing the expansion cohort size to over 36 patients per arm if the expansion is the target for the increase.

Negotiating favorable pricing and reimbursement terms with US and European payers post-approval is critical for realizing revenue. The R/M SCCHN treatment market, which NT219 addresses, is projected to reach $5 billion by 2030.

Expand existing clinical partnerships with major pharmaceutical companies to co-fund late-stage trials. Purple Biotech Ltd. already has a clinical collaboration with Bristol Myers Squibb to investigate CM24 in combination with nivolumab for metastatic pancreatic patients. Also, the company's cash position as of September 30, 2025, was $10.5 million, with a runway into the first half of 2027, meaning securing co-funding for late-stage trials is an immediate financial necessity to support pipeline advancement beyond that period.

Present compelling Phase 2 data at major oncology conferences (e.g., ASCO) to drive physician awareness and defintely adoption. The company presented final Phase 2 data for CM24 at the AACR Annual Meeting in April 2025. Furthermore, preclinical data for the CAPTN-3 platform were presented at EACR 2025.

Here's the quick math on the current financial footing supporting these penetration efforts:

Metric	Value (as of Q3 2025)	Context
Cash Position (Sep 30, 2025)	$10.5 million	Cash runway into H1 2027
Operating Loss (3 months ended Sep 30, 2025)	$1.4 million	Decrease of 35.8% year-over-year
R&D Expense (3 months ended Sep 30, 2025)	$0.6 million	Decrease of 56.4% year-over-year
CM24 Response Rate (Biomarker Subgroup)	37.5%	Phase 2 PDAC data vs. 0% control
NT219 Initial Cohort Size	10 patients per arm	Phase 2 R/M SCCHN trial

To support the pipeline, including the planned CM24 Phase 2b study, Purple Biotech Ltd. executed a public offering in September 2025, securing $6 million upfront with up to an additional $12 million from warrants, totaling a potential $18 million raise.

The current focus areas for market penetration involve maximizing the clinical data visibility:

• CM24 Phase 2b study initiation planned for second half of 2025.
• NT219 Phase 2 trial has two cohorts, potentially enrolling up to 58 patients total.
• CM24 is in collaboration with Bristol Myers Squibb.
• NT219 targets the R/M SCCHN market, projected to be $5 billion by 2030.
• Net Loss for Q3 2025 was $1.3 million.

Finance: finalize the budget allocation for expanded site activation for the NT219 trial by end of Q4 2025.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Market Development

You're looking at how Purple Biotech Ltd. (PPBT) plans to take its existing assets into new territories or new uses. This is where the real capital deployment decisions get made, and frankly, the cash runway dictates the pace.

As of September 30, 2025, Purple Biotech Ltd. held $10.5 million in cash and cash equivalents and short-term deposits. This position supports operational activities into the first half of 2027. The financial discipline shown in Q3 2025 saw an Operating Loss of $1.4 million, a decrease of 35.8 % compared to Q3 2024, largely due to reduced expenses on the CM24 Phase 2 study.

Market Development activities are inherently cash-intensive, so you need to keep an eye on the burn rate. For the three months ended September 30, 2025, Research and Development Expenses were $0.6 million, representing a 56.4% decrease year-over-year, while General and Administrative Expenses remained consistent at $0.8 million.

Here's a look at the data points relevant to expanding market reach and indication scope:

Metric/Program	Relevant Data Point (as of latest reporting)	Context for Market Development
NT219 Patent Protection	Geographic protection secured in China and Japan	Supports future regulatory filings in major Asian markets.
CM24 Phase 2 Efficacy (PDAC)	37.5% Objective Response Rate in biomarker-enriched subgroup	Data point supporting potential licensing value in European or other markets.
NT219 Phase 2 Trial Structure (R/M SCCHN)	Two single-arm cohorts, starting with 10 patients each, potential expansion to 29 patients per arm (total possible 58 patients)	Shows the structure for testing in new patient populations/indications, even if the current focus is SCCHN.
Cash Runway	Anticipated into the first half of 2027	Defines the timeline for executing market development strategies before needing further financing.

Regarding the specific steps outlined for Market Development, the following facts are on record:

• Initiate regulatory filings for NT219 in major Asian markets, specifically China and Japan, via local partners.
• The Company received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor immune evasion.
• The latest U.S. patent completes the geographic patent protection for NT219 used in combination with cetuximab in major markets, such as Europe, China and Japan.

For expanding patient populations, the current clinical work on NT219 provides a template. The Phase 1 dose escalation study concluded with two partial responses and five patients achieving stable disease when combined with cetuximab in R/M SCCHN. The subsequent Phase 2 study is evaluating NT219 in combination with either pembrolizumab or cetuximab.

The need to secure non-dilutive funding remains a constant for a company with 517,128,717 Ordinary Shares outstanding as of March 10, 2025. The September 2025 public offering brought in $6 million upfront, with up to an additional $12 million potential from warrants. This financing is intended to fund oncology drug development, working capital, and general corporate purposes. The Nasdaq minimum bid price compliance deadline is April 14, 2026.

For a potential launch in a secondary market like Canada, you'd be looking at the cost structure needed to support that. For context, the Adjusted Operating Loss for Q3 2025 was $1.3 million. Establishing a commercial footprint requires capital that must be weighed against the $1.4 million Operating Loss reported for the same period.

The CM24 program, which showed a 37.5% response rate in a specific subgroup, is also a key asset for potential licensing deals that could bring in upfront cash. The CM24 Phase 2 study expenses decreased year-over-year, contributing to the lower Q3 2025 Adjusted Operating Loss of $1.3 million.

Finance: draft 13-week cash view by Friday.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Product Development

You're looking at how Purple Biotech Ltd. plans to grow by making its existing assets do more, which is the core of Product Development in the Ansoff Matrix. This means taking CM24 and NT219-the current products-and significantly enhancing their utility through new combinations, delivery methods, or next-generation versions.

For CM24, the focus is definitely on expanding its use beyond the initial pancreatic cancer indication. The plan is to initiate a biomarker-driven Phase 2b study in the second half of $\mathbf{2025}$. This study may evaluate CM24 across multiple oncology indications, which directly addresses expanding the label.

The data supporting this expansion comes from pairing CM24 with other agents. In the randomized Phase 2 study for pancreatic ductal adenocarcinoma (PDAC), the combination of CM24, the checkpoint inhibitor Opdivo (nivolumab), and standard chemotherapy showed compelling results in biomarker-defined groups.

Here's a quick look at the efficacy seen when pairing CM24 with nivolumab and chemotherapy in PDAC:

Biomarker Subgroup	Reduction in Risk of Death	Objective Response Rate (ORR)
Serum or Tumor CEACAM1	78%	N/A
High Tumor CEACAM1 and Low PD-L1 CPS	90%	N/A
Biomarker-Enriched Subgroups (Overall)	N/A	37.5% vs 0% control

Also, consider the Phase 1 chemo-free data where CM24 combined with nivolumab showed an Overall Survival (OS) median comparable to historical third-line chemotherapy data of $\mathbf{3}$ to $\mathbf{4}$ months. One patient in that cohort survived for $\mathbf{14.6}$ months. The recommended Phase 2 dose determined from this study was $\mathbf{20mg/kg}$.

Regarding NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3 signaling pathways, the development path is focused on combination use to overcome resistance. While there is no specific financial data on formulating a subcutaneous version, the current development involves advancing it into a Phase 2 study in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) in the first half of $\mathbf{2025}$. This Phase 2 trial evaluates NT219 in combination with either pembrolizumab or cetuximab. This aligns with using the NT219 platform to screen for effective combinations against resistance mechanisms.

For next-generation research, while the prompt mentions an anti-TIGIT molecule, the most concrete, recent investment in a new modality is Purple Biotech Ltd.'s CAPTN-3 tri-specific antibody platform. The company nominated IM1305, targeting TROP2, as the second development candidate from this platform, following IM1240 (targeting 5T4). The company plans to conduct toxicology studies and initiate a Phase 1 study for IM1240 in $\mathbf{2026}$.

Financially, supporting these development steps is critical. As of September 30, $\mathbf{2025}$, Purple Biotech Ltd. reported a cash position of $\mathbf{\$10.5}$ million, anticipating a cash runway into the first half of $\mathbf{2027}$. This runway is intended to support milestones like the planned CM24 Phase 2b study and the advancement of the CAPTN-3 platform.

The strategic focus on these product enhancements is reflected in expense management:

• Research and Development Expenses decreased significantly year-over-year in Q1 $\mathbf{2025}$ by $\mathbf{76.5\%}$ to $\mathbf{\$0.8}$ million.
• Operating Loss for Q1 $\mathbf{2025}$ was $\mathbf{\$1.4}$ million, a $\mathbf{68.9\%}$ reduction YoY.
• The overall cash runway extends into $\mathbf{H1\ 2027}$.

Purple Biotech Ltd. (PPBT) - Ansoff Matrix: Diversification

Acquire a preclinical-stage gene therapy platform focused on a non-oncology therapeutic area, like rare genetic disorders.

The global gene therapy market size is calculated at USD 11.4 billion in 2025. In the U.S., rare diseases impact 15.5 million individuals, resulting in annual medical costs of USD 997 billion. A comparable investment occurred in May 2025, where one biotech entity invested $85 million to start creating a new class of in vivo genetic drugs. Early-stage research and development costs for clinical stage biotechnology candidates frequently exceed tens of millions of dollars for each candidate. Purple Biotech Ltd. reported a cash position of $10.5 million as of September 30, 2025, with a runway into the first half of 2027. Research and Development Expenses for Purple Biotech Ltd. in Q3 2025 were $0.6 million.

Establish a diagnostics division to develop companion diagnostics for CM24, ensuring patient selection accuracy.

The Companion Diagnostics Market is estimated to be valued at USD 6,059.1 million in 2025. Molecular diagnostics led this market with a share of 49.1% in 2025. Industry estimates suggest the cost to properly develop and commercialize a novel diagnostic in the US can range from $20 million to $106 million. Purple Biotech Ltd.'s lead asset, CM24, showed a 90% reduction in mortality risk in biomarker-enriched subgroups in its Phase 2 trial. The company planned for a Phase 2b study for CM24 in the second half of 2025.

Metric	Purple Biotech Ltd. (Q3 2025)	Diagnostics Industry (2025 Estimate)
Cash Position/Market Value	$10.5 million (Cash)	$6,059.1 million (Market Value)
R&D/Development Cost	$0.6 million (Q3 2025 R&D Expense)	$20 million to $106 million (Diagnostic Dev/Commercialization Range)

Enter a strategic joint venture with a medical device company to integrate drug delivery with a novel technology.

The clinical stage biotechnology market is seeing consolidation, with M&A deals often valued in the hundreds of millions to billions of dollars. Purple Biotech Ltd. is advancing its CAPTN-3 platform, with an Investigational New Drug (IND) submission for IM1240 expected in 2026. The company's NT219 Phase 2 trial in head and neck cancer was initiated in June 2025.

Out-license the intellectual property for a non-core asset to a specialty pharma company for a guaranteed royalty stream.

Purple Biotech Ltd. reported a net loss of $1.3 million for the three months ended September 30, 2025. The company's operating loss decreased by 35.8% year-over-year for Q3 2025 to $1.4 million. The company secured up to $18 million in a public offering, with $6 million upfront and up to an additional $12 million from warrants.

Leverage the company's expertise in immune-oncology to start a new program in infectious disease vaccines.

In the Cell and Gene Therapy Market, the infectious disease segment is expected to hold the largest market share in 2024. Purple Biotech Ltd. has focused on oncology, with pipeline assets including CAPTN-3, CM24, and NT219. The company reduced its operating expenses, with Q3 2025 General and Administrative Expenses at $0.8 million, consistent with Q3 2024. This cost management discipline is defintely a factor in their runway extension.

• Purple Biotech Ltd. Q3 2025 Cash Position: $10.5 million.
• Purple Biotech Ltd. Q1 2025 R&D Expense Reduction: 76.5% year-over-year.
• Gene Therapy Market CAGR (2025-2034): 20%.
• CM24 Efficacy in Biomarker Subgroups: 90% mortality risk reduction.